Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
- Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Can A Biotech Create A CDMO Market?
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Background-Free Analysis Of Mouse TILs
Syngeneic mouse tumor models are crucial for immunotherapy research, but variability in TILs and nonspecific binding complicate analysis. Discover how blocking reagents help but make the process more labor-intensive.
-
Streamlining AAV And LVV Manufacturing Platform Solutions
Observe how streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.
-
Powering More Efficient Clinical Development With AI And ML
Explore how AI and ML are revolutionizing clinical trials by automating data processes to accelerate research and transform data into actionable outcomes for patient care.
-
Implementing Medium And High-Volume Drug Handling And Packaging Programs
Simplify the complexity of combination product development by partnering for integrated support across device design, industrialization, manufacturing, and final product assembly.
-
Assessment Of Compound Toxicity Effects With High-Content Imaging
3D cellular models and bioprinting enhance drug safety predictions and offer precise spatial control. Explore an automated method for generating liver models to improve reproducibility and reliability in toxicity testing.
-
Optimized Transient Transfection Platform: AAV Program From Gene To GMP
Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.
-
AI-Enabled Phenotypic Analysis Of Label-Free Intestinal Organoids
Discover how advanced 3D models and AI-enabled imaging techniques revolutionize organoid research, which provides accurate phenotypic analysis to monitor growth and development in various organoid types.
-
Enhancing AAV Production Performance And Economics
Enzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.
-
Comparison Of Different Methods To Isolate HMW DNA From Bacteria
Different extraction methods produce dramatically different DNA sizes and qualities, directly affecting long‑read sequencing results. See how performing early QC can improve sequencing success.
-
Determining The Power Numbers For A Single-Use Mixing System
In designing a mixing process for scale-up, the power number is a critical parameter. Explore the determined power numbers for a single-use mixer at various mixing speeds and fill levels.
NEWSLETTER ARCHIVE
- 05.15.26 -- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- 05.14.26 -- Discover critical components for fluid management and flow control
- 05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- 05.13.26 -- Manufacturing Moves Shaping Advanced Therapies
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections